Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin to modify tumor hypoxia in locally advanced cervical cancer
2018-004119-36Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in Cervical Cancer (CC), sponsored by Oslo University Hospital. Primary endpoint: Change in tumor hypoxia-related gene expression signature after one week of metformin. Started Jun 2019; status: completed.
02
Drugs
metformin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2018-004119-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004119-36.